APNAR Pharma, headquartered in Chino, CA has acquired East Windsor, NJ-based Aurex Laboratories for an undisclosed amount. This acquisition enhances APNAR’s capabilities, scale, and global footprint and broadens APNAR’s pipeline.

“As part of our well-defined strategy and commitment of having manufacturing in the U.S., we are excited to acquire Aurex,” said Dharmesh Patel, president of APNAR. “This milestone will position APNAR as a company with global footprint in the U.S. and India. In addition to developing and manufacturing APNAR’s own products, we are looking forward to working in a collaborative manner with other companies for contract and co-development and contract manufacturing.”

Sanjay Bhargav, COO of APNAR, said, “In addition to adding state-of-the-art facility to APNAR’s capabilities in the U.S., we are pleased to welcome to APNAR an amazing team that is experienced, highly capable, and dedicated including scientists, manufacturing, regulatory, and project management personnel. We look forward to manufacturing APNAR’s 5 ANDAs and other drugs in the US to ensure supply chain security and excellence.”

APNAR Pharma is a privately owned pharma company that develops, manufactures, packages, sells, markets and distributes generic pharmaceuticals and OTCs. The company has R&D and manufacturing facilities in East Windsor, NJ and Gavasad, Gujarat, India.